New hope for kids with tough leukemia: testing gentler, targeted treatment
NCT ID NCT07387926
Summary
This study is testing a new combination of drugs for children and young adults (ages 1-30) whose acute lymphoblastic leukemia (ALL) has come back or hasn't responded to other treatments. The goal is to see if adding a new targeted drug (asciminib) to a lower-dose chemotherapy and another immunotherapy drug (blinatumomab) is safe and can help get the cancer into remission. The study will first find the best dose and then see how well the full treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.